Spojené státy - angličtina - NLM (National Library of Medicine)

hysan pharmaceutical co ltd - methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et) - methyl salicylate 40 g in 100 ml - purpose: external analgesic uses temporarily relieves minor aches, muscles and joint pains due to: - simple backache - arthritis - strains - sprains - bruises do not use - on opened wounds - on damaged skin stop use and ask a doctor if - a rash or irritation develops - condition worsens - symptoms persist for more than 7 days or clears up and occur again within a few days

Spojené státy - angličtina - NLM (National Library of Medicine)

pharmaceutica north america, inc. - methyl salicylate (unii: lav5u5022y) (methyl salicylate - unii:lav5u5022y), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - methyl salicylate 24 g in 120 g - for temporary relief of minor aches and pains of the muscles and joints associated with simple arthritis, sprains, bruises and simple backache.

Spojené státy - angličtina - NLM (National Library of Medicine)

laderma trading pty ltd - methyl salicylate (unii: lav5u5022y) (methyl salicylate - unii:lav5u5022y) - methyl salicylate 105 mg in 1 g - pain relieving - for the temporary relief of minor aches and pains of muscles and joints associated with simple backache, arthritis, strains, bruises and sprains.

Spojené státy - angličtina - NLM (National Library of Medicine)

abbp (arrington, battle, bell & perry), llc - methyl salicylate (unii: lav5u5022y) (methyl salicylate - unii:lav5u5022y), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a) - methyl salicylate 30 ml in 100 ml - topical analgesic for the temporary relief of minor aches and pains of muscles and joints associated with simple backaches, arthritis, bruises, sprains and strains. - condition worsens - symptoms persist for more than seven (7) days - symptoms clear up and occur again within a few days.

Malajsie - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

natural wellness industries sdn. bhd. (milik penuh nutrivention sdn. bhd) - methyl salicylate -

Malajsie - angličtina - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

natural wellness industries sdn. bhd. (milik penuh nutrivention sdn. bhd) - methyl salicylate -

Filipíny - angličtina - FDA (Food And Drug Administration)

methyl salicylate , menthol , eucalyptus oil - liniment oil classification: household remedy (hr) - 27 mg/ 25 mg/ 6 mg per 100 ml dosage

Spojené státy - angličtina - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - methylprednisolone acetate (unii: 43502p7f0p) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone acetate 40 mg in 1 ml - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenita

Spojené státy - angličtina - NLM (National Library of Medicine)

teva parenteral medicines, inc. - methylprednisolone acetate (unii: 43502p7f0p) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone acetate 40 mg in 1 ml - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. to tide the p

Spojené státy - angličtina - NLM (National Library of Medicine)

proficient rx lp - methylprednisolone acetate (unii: 43502p7f0p) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone acetate 40 mg in 1 ml - when oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension usp is indicated as follows: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with can